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Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS). Many believe autoimmune pathogenesis plays a key role in MS, but
its target(s) remains elusive. A recent study detected autoantibodies against KIR4.1,
an ATP-sensitive, inward rectifier potassium channel, in nearly half of the MS patients
examined. KIR4.1 channels are expressed in astrocytes. Together with aquaporin
4 (AQP4) water channels, they regulate astrocytic functions vital for myelination.
Autoantibodies against AQP4 have been established as a key biomarker for neuromyelitis
optica (NMO) and contributed to diagnostic and treatment strategy adjustments.
Similarly, identification of KIR4.1 autoantibodies could have high therapeutic values in
treating MS. Consistent with its potential role in MS, KIR4.1 dysfunction is implicated in
several neurological disorders. However, the enrichment of KIR4.1 autoantibodies in MS
patients is questioned by follow-up studies. Further, investigations are needed to clarify
this controversy and unravel the underlying mechanisms of MS pathogenesis.
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MS affects the brain and spinal cord of over two million people worldwide. The primary MS
pathology includes immune-mediated destruction of myelin sheaths and axon degeneration. Early
MS symptoms include fatigue, walking difficulties, blurred vision, and numbness, tingling, and
weakness of the limbs or other parts of the body. Others include muscle stiffness, cognitive deficits,
and urinary problems. The cause (etiology) of MS is still unknown, but it is believed several
interacting factors are involved, such as genetic, environmental, infectious, and most importantly,
immunological factors. Antibody-generating B cells, as well as cytotoxic T cells, are most likely
involved in the abnormal autoimmune attack of myelin and axons common inMS. The importance
of B cells in the autoimmune pathogenesis of MS is supported by increased immunoglobulins in
the cerebrospinal fluid (CSF) and demyelinated lesions in the CNS of MS patients, as well as by
the B-cell-depleting monoclonal antibody, rituximab, which decreases MS relapses (Hauser et al.,
2008). However, although specific autoantibodies in MS patients have been targets of intensive
investigation for decades, the identification of autoantigen(s) in MS still remains elusive. The
discovery of potential autoantigen in MS often gives rise to controversy. KIR4.1 channel was
recently identified to play a key role in the MS pathogenesis (Srivastava et al., 2012), but has
debatable potential as a candidate autoantigen.
KIR channels (KIR1 to KIR7) are inwardly rectifying channels, which have a greater tendency
to allow K+ ions to flow into, rather than out of, a cell. These KIR channels are not sensitive
to dalfampridine [4-aminopyridine (4-AP)], which is currently used for symptomatic treatment
of MS, particularly for improving walking in MS patients [see reviews for detailed information
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FIGURE 1 | Schematic diagrams of KIR4.1 structure and localization in
astrocyte endfeet. (A) Structural diagrams of KIR4.1 (left) and Kv channel
(right) subunits. N, the N-terminus; C, the C-terminus; P, the P-loop. The
region near the P-loop (residues 83–120) is the putative site recognized by the
autoantibodies (Srivastava et al., 2012). 4-Aminopyridine blocks some Kv
channels but not KIR channels. (B) Astrocyte endfeet interact with synapses
(left), blood vessels (middle) or myelin membranes (right).
(Judge and Bever, 2006; Blight et al., 2014)]. It is believed
that the beneficial effect of 4-AP results from restoring axonal
conduction by blocking voltage-gated K+ (Kv) channels that are
exposed in demyelinated axons. However, 4-AP does not cure
MS and blocks many types of Kv channels that are broadly
expressed in the nervous system. KIR channels are different
from Kv channels in terms of both structure and function. The
KIR α-subunit contains two transmembrane domains and one
pore-forming loop (Figure 1A). Four KIR α-subunits homo- or
hetero-tetramerize to assemble into a functional channel. KIR
channels are also insensitive to another Kv channel blocker
tetraethylammonium, but can be blocked by Ba2+. Among about
80 genes in the K+ channel superfamily, 15 KIR α-subunits have
been identified in humans and rodents with different biophysical
and pharmacological properties, and patterns of tissue expression
and subcellular localization. KIR4.1 is an intermediate inward
rectifier and can bind to adenosine triphosphate (ATP) and
PtdIns(4,5)P2 (Hibino et al., 2010).
KIR4.1 channels are expressed in the CNS and usually
localize in astrocytic endfeet (Figure 1B). These channels
play an important “K+ buffering” role, removing K+ ions
from extracellular spaces surrounding astrocytes adjacent to
blood vessels and synapses. KIR4.1 reduction can cause
neuronal dysfunction and seizure activity in animals. Globally
deleting KIR4.1 in mice causes impaired myelination and
oligodendrocyte maturation during development, leading to
neuronal degeneration and mice surviving only until around
2–3 weeks of age (Neusch et al., 2001). Mice with a KIR4.1
genetic polymorphism display increased seizure susceptibility,
likely resulting from impaired astrocytic K+ and glutamate
uptake (Inyushin et al., 2010). Conditionally deleting KIR4.1
from GFAP (glial fibrillary acidic protein)-positive astrocytes in
mice also caused impaired K+ and glutamate uptake, leading
to ataxia, seizures, and premature death (Djukic et al., 2007).
Therefore, KIR4.1 is critical for the proper functions of astrocytes
vital for the CNS.
Although oligodendrocytes and T lymphocytes are the main
focus of MS research, there has been a surge of interest in
studying astrocytes in the pathogenic process of MS. Astrocytes
are a diverse group of non-neuronal cells and the most abundant
cell type in the brain. They can be divided into three major
types: protoplasmic astrocytes (in gray matter), fibrous astrocytes
(in white matter), and radial glial cells. Through their endfeet,
astrocytes regulate synaptic transmission, blood-brain barrier,
and myelination (Figure 1B). Astrocytic dysfunction has also
been implicated in Alzheimer’s disease, Huntington disease,
epilepsy, stroke, and a variety of other neurological disorders
and conditions (see a recent review, Pekny et al., 2016). In MS,
astrocytes can regulate the pathogenesis by acting as part of
the innate immune system, releasing soluble factors including
trophic factors to promote remyelination, forming a glial scar to
inhibit remyelination and axonal regeneration, and maintaining
the proper function of the neurovascular unit [see recent reviews
for detailed information (Brosnan and Raine, 2013; Nualart-
Marti et al., 2013; Ludwin et al., 2016). More extensive discussion
of astrocytes in MS and neurological disorders is beyond the
scope of this review article.
KIR4.1 channel has been linked to demyelinating conditions.
By screening serum IgG from MS patients, Srivastava et al.
recently identified IgG1 and IgG3 antibodies that can specifically
bind to glial cells in the CNS of humans and rats (Srivastava et al.,
2012). Using enriched IgG fraction, they immunoprecipitated
lysates of human brain tissue and identified precipitated
proteins with tandem mass spectrometry. One of the identified
proteins was KIR4.1. A series of assays including enzyme-linked
immunosorbent assay (ELISA) and Western blotting were used
to confirm KIR4.1 as a target of the autoantibody response
in MS (Srivastava et al., 2012). Importantly, the study showed
that serum levels of antibodies to KIR4.1 were higher in MS
patients (about 47% of 397) than persons with other neurologic
diseases (about 1% of 329) and healthy donors (0% of 59). These
antibodies appeared to bind to the peptide (residues 83–120)
corresponding to the first extracellular loop of KIR4.1, and thus
can bind to the channel without entering the cell. Furthermore,
injection of KIR4.1 serum IgG into the cisternae magnae of mice
caused a profound loss of KIR4.1 expression, altered expression
of GFAP in astrocytes, and activation of the complement cascade
at sites of KIR4.1 expression in the cerebellum. Based on these
results, the authors proposed that KIR4.1 is an autoimmune
target in some MS patients (Srivastava et al., 2012). Later,
Krau et al. from the same research group further showed that
serum antibodies to KIR4.1 were present in more than half of
children with acquired demyelinating disease but not in children
with other diseases or in healthy controls (Kraus et al., 2014).
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This study suggests that KIR4.1 is also an important target of
autoantibodies in childhood acquired demyelinating disease.
The KIR4.1 study in MS autoimmune pathogenesis drew an
interesting comparison to the role of a water channel, AQP4,
as an important autoimmune target in another inflammatory
demyelinating disease, NMO (Lennon et al., 2004; Waters and
Vincent, 2008; Hinson et al., 2012). NMO was thought to
be one form of MS until the discovery of the autoantibody
in NMO suggesting different mechanisms governing NMO
and MS pathogeneses. Different from MS, NMO is a primary
astrocytopathy with secondary demyelination. MS and NMO
also differ in pathological and imaging features, as well as in
their responses to different immunotherapies (see recent reviews,
Barnett and Sutton, 2012; Jukkola and Gu, 2015). In the CNS,
AQP4 is predominantly localized to astrocytic endfeet contacting
blood capillaries and synapses, similar to KIR4.1 (Figure 1B).
The colocalization led to the hypothesis that the two channels
functionally interact to regulate water and K+ homeostasis.
However, they unlikely interact directly, since KIR4.1 channel
expression and function remain unchanged in AQP4 knockout
mice, and inhibition or knockdown of KIR4.1 does not change
the AQP4 water permeability (Ruiz-Ederra et al., 2007; Zhang
and Verkman, 2008). Nonetheless, besides direct regulation of
water homeostasis, AQP4 can indirectly regulate K+ homeostasis
through its effect on extracellular space volume, for instance
during synaptic stimulation (Haj-Yasein et al., 2015). It is
important to note that APQ4 autoantibody was present in only
about 65% of NMO patients, and completely absent in the serum
of MS patients, whereas KIR4.1 autoantibody was suggested to
be present in about half of MS patients (Srivastava et al., 2012).
Therefore, it seems that additional targets of autoantibodies must
be present in both NMO and MS.
Mutations in KIR4.1 have been linked to epilepsy, ataxia and
deafness in in humans (Bockenhauer et al., 2009). Hippocampal
sclerosis in temporal lobe epilepsy appears to be associated
with loss of KIR4.1 in astrocytic endfeet (Heuser et al., 2012).
In animal models of epilepsy, disruption of the blood brain
barrier led to serum albumin leakage into the CNS and
uptake by astrocytes, leading to downregulation of KIR4.1 and
the development of neuronal hyperexcitability and epileptic
activity (Cacheaux et al., 2009). Reduced KIR4.1 activity
causes increased extracellular K+ and glutamate, contributing
to brain hyperexcitability and epileptogenesis. Furthermore,
deficits of astrocytic KIR4.1 channel may contribute to neuronal
dysfunction in the mouse model of Huntington’s disease (Tong
et al., 2014). As a result of KIR4.1 reduction, extracellular K+
levels measured by K+-selective microelectrodes were elevated
from 1.5 mM (under control condition) to about 3.0mM,
which significantly depolarized striatal medium spiny neurons
by ∼6 mV (e.g., from −75 to −69 mV) and increased their
excitability. This can be rescued by over-expressing functional
KIR4.1, leading to ameliorated deficits associated with the mouse
models (Tong et al., 2014). A spinal cord injury model showed
up to 80% reduction in Kir4.1 expression in the lesion area,
and demonstrated that a previously discovered neuroprotective
agent, 17-β-oestradiol, could partially restore KIR4.1 expression
and function (Olsen et al., 2010).
Although KIR4.1 channel appears to be a plausible target
of the antibody response in MS pathogenesis, the subsequent
and independent studies have provided inconsistent results and
casted doubt regarding whether there is indeed an increase
of KIR4.1 autoantibodies in MS patients. Using ELISA with
synthetic human KIR4.1 peptide (residue 83–120), Nerrant et al.
found KIR4.1 autoantibodies in serum from only 7.5% of MS
patients (total 268), 4.3% of patients with other neurological
diseases (total 46) and 4.4% of healthy controls (total 45;
Nerrant et al., 2014). Using the same peptide-based ELISA and
immunostaining, Brickshawana et al. failed to detect KIR4.1-
specific IgG in serum or CSF from MS patients, or any KIR4.1
loss from glia in MS lesions (Brickshawana et al., 2014). In
this study, the investigators tested 229 population-based and
57 clinic-based MS patients, 99 healthy controls, and 109
disease controls (Brickshawana et al., 2014). On the other hand,
using the peptide-based ELISA, Brill et al. identified KIR4.1
autoantibodies in serum from 21 of 80 MS patients, 10 of
45 NMO patients, and 2 of 32 healthy controls (Brill et al.,
2015). Interestingly, KIR4.1 antibody levels appeared to be
higher during relapse than remission in MS patients, so the
antibody may represent a marker of disease exacerbation (Brill
et al., 2015). In these three more recent and relatively negative
studies, the peptide-based (KIR4.1 residue 83–120) ELISA was
used, whereas the whole-KIR4.1-based ELISA was used in the
prior two positive studies from the same group (Srivastava
et al., 2012; Kraus et al., 2014). The channel peptide may not
have the same conformation as in a native channel complex
to be recognized by the antibodies. Moreover, glycosylation
present in the native channel is not reflected in the peptide.
For instance, within the first extracellular loop (83–120) of
KIR4.1, there is a potential N-linked glycosylation site at
N104 (NHT). Therefore, it is possible that antibodies bind to
the whole channel but not to the synthetic peptide of the
binding site.
In order to resolve the controversy regarding whether KIR4.1
autoantibodies are present in MS patients, two additional studies
from independent groups performed the whole-KIR4.1-based
ELISA and published their results in the New England Journal
of Medicine in 2016. In the first study, the full-length KIR4.1
channel protein was expressed in HEK293 cells and purified.
This procedure allowed for KIR4.1 native tetrameric assembly
and isolation of low-glycosylated KIR4.1 isoforms, which are
critical for autoantibody binding. Chastre et al. performed the
assay using detailed instructions provided by the authors of the
original report during a visit to their laboratory as part of a
collaborative scientific exchange. After testing serum from 86
clinic-based MS patients and 51 healthy control donors, none
of the samples showed KIR4.1 reactivity and no significant
difference was established between MS patient and control group
(Chastre et al., 2016). Due to technical difficulties including
the impact of high-order structure formation of the KIR4.1
channel complex and post translational modifications on KIR4.1-
antibody binding, Chastre et al. concluded that further studies
are required to clarify the presence of KIR4.1 autoantibodies
in MS, including investigations through cooperative sharing of
specimens (Chastre et al., 2016).
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In the second study, Probstel et al. performed a large,
blinded study testing serum samples from 141 MS patients
and 131 controls, with both a protein and a peptide ELISA,
and failed to detect a significant difference between MS and
control groups in KIR4.1 autoantibodies (Probstel et al., 2016).
This study further suggested that the whole-protein ELISA
might reveal serum reactivity directed against non-KIR4.1
proteins copurified with KIR4.1 (Probstel et al., 2016). Despite
the negative result, the authors also cautioned the specificity
of ELISA technique for detecting KIR4.1 autoantibodies and
suggested further investigation (Probstel et al., 2016). Taken
together, KIR4.1 channel cannot currently be established as an
important autoimmune target in MS pathogenesis.
Another recent study failed to detect enriched KIR4.1
autoantibodies in Japanese patents with MS (57 patients)
or NMO (40 patients including NMO spectrum disorders),
compared to 50 healthy controls (all were Japanese; Higuchi et al.,
2016). ELISA using a synthetic peptide of the first extracellular
portion of human KIR4.1 (residues 83–120) did not reveal even a
single positive in serum samples from those patients. Antibodies
against the full length KIR4.1 were detected in only two MS
patients and in none of NMO patients (Higuchi et al., 2016).
Nonetheless, since anti-KIR4.1 autoantibodies were detected
at a very low frequency in MS patients, the authors suggest
that at least currently serum testing for human KIR4.1-specific
antibodies is unlikely to improve the diagnosis of MS in Japanese
patients.
Regardless of whether KIR4.1 autoantibodies are enriched in
MS patients, further investigations are still needed to identify the
target(s) of the antibody response inMS, as well as in NMO. Even
in NMO, AQP4 autoantibodies are not present in every patient,
suggesting the presence of other target(s). To unequivocally
identify the target(s) of MS autoantibodies, future investigations
need cooperative studies using shared serum samples from
MS patients and healthy controls, as well as established
detection procedures and reagents. However, it is perhaps
more important to clarify first whether the autoantibodies
are pathogenic or only byproducts from degenerative process
of astrocytes in the CNS during disease progression. For
instance, it is not yet clear whether autoantibodies have to
bind the extracellular portion of the channel, or can be first
internalized and subsequently bind to intracellular portion
of the channel. How antibodies alter channel functions still
remains unknown. Furthermore, astrocytic KIR4.1 channel
does not likely operate alone. Its binding proteins and other
proteins involved in regulating astrocytic functions, such as
KIR5.1 and AQP4, could also be the target causing similar
disruption, and are worth of pursuing. Indeed, many ion
channel proteins have been identified to express in resting or
activated astrocytes (Jukkola and Gu, 2015). They include Kv
channels, two-pore K+ channels, several voltage-gated Ca2+
and Na+ channels, transient receptor potential channels, and
gap junctions (Jukkola and Gu, 2015). Their disruption also
likely causes dysfunction of astrocytic signaling, leading to CNS
malfunction. In sum, further investigation in this field will
contribute to a better understanding of the immune pathogenesis
of MS, as well as the development of new treatments for
autoimmune diseases.
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